4D Molecular Therapeutics, Inc. (FDMT)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
4D Molecular Therapeutics, Inc. (FDMT) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
4D Molecular Therapeutics, Inc. (FDMT) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Tops Revenue Estimates
4D Molecular Therapeutics, Inc. (FDMT) came out with a quarterly loss of $1.04 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.98 per share a year ago.
10 Stock Picks to Celebrate 45 Years of Schaeffer's
Subscribers to Chart of the Week received this commentary on Sunday, July 26.
4D Molecular Therapeutics, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 1 | $9.33 | $12.2 | $2.87 | 30.76% |
| BZ Brandon Zatopek Commonwealth Equity Services LLC | 28,574 | $329,172.48 | $348,602.8 | $19,430.32 | 5.9% |
| KM Kristin Mariani Janus Henderson Group PLC | 4.64M | $55.17M | $56.28M | $1.11M | 2.02% |
| CD Charlie Durham Sterling Capital Management LLC | 924 | $8,029.56 | $11,272.8 | $3,243.24 | 40.39% |
 Anthony Scaramucci SkyBridge Capital II LLC | 2M | $17.06M | $24.7M | $7.64M | 44.82% |
4D Molecular Therapeutics, Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| TA Tazeen Ahmad B of A Securities | 21,018.48 | $304,557.77 | $259,578.23 | -$44,979.54 | -14.77% |
4D Molecular Therapeutics, Inc. (FDMT) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has 4D Molecular Therapeutics, Inc. ever had a stock split?
4D Molecular Therapeutics, Inc. Profile
| Biotechnology Industry | Healthcare Sector | David H. Kirn CEO | NASDAQ (NGS) Exchange | 35104E100 CUSIP |
| US Country | 196 Employees | - Last Dividend | - Last Split | 11 Dec 2020 IPO Date |
Overview
4D Molecular Therapeutics, Inc., established in 2013 and based in Emeryville, California, is a pioneering clinical-stage biotherapeutics company dedicated to advancing genetic medicine. Leveraging their proprietary therapeutic vector evolution platform, the company significantly contributes to the genetic medicine field across the Netherlands and the United States. 4D Molecular Therapeutics, Inc. is at the forefront of developing product candidates in three critical therapeutic areas - ophthalmology, cardiology, and pulmonology. Their development strategy encompasses a wide array of genetic treatments aimed at addressing significant unmet medical needs, underscored by collaborative efforts with institutions like Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc.; uniQure biopharma B.V.; and the Cystic Fibrosis Foundation.
Products and Services
- 4D-150: This product is in phase 1/2 clinical trial, aimed at treating wet age-related macular degeneration and diabetic macular edema. 4D-150 illustrates the company's commitment to combating severe ophthalmological conditions, offering hope for conditions that lead to vision loss.
- 4D-125: Currently in a phase 1/2 clinical trial, 4D-125 is being developed to treat x-linked retinitis pigmentosa, a genetic condition that causes progressive vision loss. This product highlights the company's focus on addressing rare ophthalmic diseases through advanced genetic treatments.
- 4D-110: This candidate is in phase 1/2 clinical trials for choroideremia treatment, a rare inherited disorder that also results in progressive loss of vision. 4D-110 is representative of 4D Molecular Therapeutics’ efforts to provide solutions for lesser-known, yet impactful, ophthalmological conditions.
- 4D-710: In phase 1/2 clinical trial, 4D-710 is geared towards treating cystic fibrosis lung disease. This product candidate embodies the company's dedication to addressing pulmonary conditions with a genetic approach, potentially offering a novel treatment option for cystic fibrosis patients.
- 4D-310: Also in phase 1/2 clinical trial, 4D-310 is developed for treating Fabry disease cardiomyopathy. This treatment illustrates the company’s innovative approach to cardiology, targeting genetic disorders that affect the heart.
- 4D-175: Currently in pre-clinical development, 4D-175 is designed for the treatment of geographic atrophy. This candidate expands the company's ophthalmology portfolio by targeting the advanced stage of age-related macular degeneration, focusing on a condition that leads to severe vision loss and blindness.
- 4D-725: Aimed at treating alpha-1 antitrypsin deficiency lung disease, this product is in pre-clinical development. 4D-725 signifies the company’s forward-thinking approach to pulmonology, targeting genetic disorders that impair lung function.
Contact Information
